Clinical trials: Healthy Young
Gram-negative Bacterial Infection
Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.
- Trial name
- NCT01015014
- Testing
- AN3365
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Controls
Normative Data of Brain Network Activation in Adolescents and Young Adults
Establish normative data of ElMindA's Brain Network Activation (BNA) using evoked response in two age groups: adolescents and young adults.
- Trial name
- NCT01460394
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Diabetes
First in Man Study With SLV341
First in man study with single and multiple rising doses with SLV341
- Trial name
- NCT00887445
- Testing
- SLV341
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Focus of Study is Healthy Chinese Lactating Mother 0-270 Days
Evaluation of the Nutrients Composition of Breast Milk of Chinese Lactating Mothers and Their Nutrition Intake
To understand breast milk composition during different lactating stages.
- Trial name
- MING (NCT01971671)
- Testing
- no intervention.
- Where
- China
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Substance-related Disorders, Alcohol-Related Disorders
LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School
LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.
- Conditions
- Substance-related Disorders, Alcohol-Related Disorders, Tobacco Use Disorder, Marijuana Use
- Trial name
- NCT07655609
- Testing
- Introduction, Norms re: Protective Behavior Strategies (PBS), Life Skills
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Prevention Strategies, LLC
Healthy
A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers
Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.
- Trial name
- SRD (NCT00583544)
- Testing
- TC-2216
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Hypertension
A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)
The goal of this study is to identify at least one safe and well tolerated dose of MK1809 that has similar pharmacokinetic qualities as 100 mg losartan.
- Trial name
- NCT01033318
- Testing
- MK1809, Comparator: Losartan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Pain
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject
This study is to evaluate the safety of AMG 403 in healthy adult subjects. The study consists of a 21 day screening period followed by administration of the investigational product and up to 154 day evaluation period.
- Trial name
- NCT02348879
- Testing
- AMG 403
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Amgen
Normal, Healthy Volunteers
A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.
- Trial name
- NCT01744808
- Testing
- EB-1020 IR, EB-1020 SR1, EB-1020 SR2
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Contraception
Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)
The purpose of this study is to examine and compare the uptake of Yasmin (oral contraceptive containing drospirenone and ethinylestradiol) with or without levomefolate calcium (Metafolin, a registered vitamin supplement) in the…
- Trial name
- NCT01253174
- Testing
- EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131), EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca), L-5-MTHF Ca 0.451 mg (Metafolin)
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Young Men
A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants
The main goals of the study are to assess uptake and distribution of Lu AF90103 in the brain when given at tracer levels (microdose) in healthy young men.
- Trial name
- NCT05306366
- Testing
- [11C]-Lu AF90103
- Where
- Sweden
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Streptococcus Pneumoniae, Haemophilus Influenzae
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of a non-typable Haemophilus influenzae and pneumococcal candidate vaccine in young adults.
- Trial name
- NCT00814489
- Testing
- GSK2231395A, Engerix-B
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension, Chronic Heart Failure
Pharmacokinetics of BIA 5-453 and Its Metabolites
The purpose of this study was to assess the effects of age on the pharmacokinetic (PK) profile of BIA 5-453 and its metabolites.
- Trial name
- NCT03090724
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Influenza
Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)
The purpose of this Phase II follow-up study (to study 810501) is to assess the immunogenicity and safety of a booster vaccination with a non-adjuvanted H5N1 influenza vaccine administered 12 to 17 months after a two-dose regimen…
- Trial name
- NCT00530660
- Testing
- H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted
- Where
- Austria
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Healthy
A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
This is a single centre, three single administrations (Days 1, 29 and 57) at increasing doses of IMP321 (3, 10, 30 and 100 µg) in four cohorts of 12 subjects, single blind, randomized study.
- Trial name
- NCT00354861
- Testing
- hepatitis B antigen (without alum) plus IMP321, hepatitis B antigen alone (without alum), Engerix B
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Immutep S.A.S.
Healthy Subjects, Pharmacokinetics of ASP6294
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
The purpose of this study is to evaluate the safety and tolerability of single ascending intravenous doses and single subcutaneous (sc) doses of ASP6294 in healthy young male and female subjects.
- Trial name
- NCT02681861
- Testing
- ASP6294 Intravenous, ASP6294 Subcutaneous
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
The main objectives of this trial are to investigate safety and tolerability of BI 474121 in healthy male and female young and elderly subjects following oral administration of multiple rising doses per day over 14 days.
- Trial name
- NCT04537897
- Testing
- BI 474121, Midazolam
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Deep Vein Thrombosis Leg
A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting
This will be a study existing of 4 periods, to evaluate for a single dose of 4 different tablets of DPOC-4088 the absorption and elimination from the body and the potential effect on blood clotting.
- Trial name
- NCT01347203
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals